QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Taylor, L. M Articles by Kuhn, R. J Search for Related Content PubMed PubMed Citation Articles by Taylor, L. M Articles by Kuhn, R. J

DRUG INFORMATION ROUNDS

Hypertonic Saline Treatment of Cystic Fibrosis

at time of writing, Pediatric Specialty Pharmacy Resident, Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, UK HealthCare, Lexington, KY; now, Pediatric Clinical Pharmacy Specialist, Shands Hospital at the University of Florida, Gainesville, FL

Robert J Kuhn, PharmD

Pediatric Clinical Pharmacy Specialist, Department of Pharmacy, University of Kentucky Medical Center, UK HealthCare; Professor, College of Pharmacy, University of Kentucky

Reprints: Dr. Kuhn, Department of Pharmacy, University of Kentucky Medical Center, UK HealthCare, 800 Rose St., C-113, Lexington, KY 40536, fax 859/323-2049, rjkuhn1{at}email.uky.edu

OBJECTIVE: To review the literature concerning the use of hypertonic saline (HS) in patients with cystic fibrosis and explain the rationale for its use.

DATA SOURCES: A MEDLINE search was conducted through February 2007. Search terms included hypertonic saline, mucociliary clearance, cystic fibrosis, and human DNASE 1 protein. Additional data were identified through subsequent bibliographic reviews.

STUDY SELECTION AND DATA EXTRACTION: All articles in English identified from the data sources were evaluated. Pertinent studies using HS in patients with cystic fibrosis were included in the analysis.

DATA SYNTHESIS: Cystic fibrosis is caused by a deficiency in the cystic fibrosis transmembrane regulator gene, resulting in reduced chloride secretion and excessive sodium absorption. The most significant changes are seen in the airway lumen of the lungs. HS has been shown to improve mucociliary clearance versus placebo. A short-term efficacy trial showed a modest and variable increase in forced expiratory volume in 1 second (FEV₁) over a 2 week period (15.0 ± 16.0% from baseline vs 2.8 ± 13.1% with HS 6% and NaCl 0.9%, respectively; p = 0.004). A long-term efficacy trial of either HS 7% or NaCl 0.9% twice daily for 48 weeks has shown a modest sustained improvement in FEV₁ and a significantly increased exacerbation-free survival rate (76% vs 62% for HS 7% and NaCl 0.9%, respectively; p = 0.03).

CONCLUSIONS: HS preceded by a bronchodilator is an inexpensive, safe, effective additional therapy in cystic fibrosis patients with stable lung function. Its use has been associated with a modest improvement in lung function and reduced frequency of pulmonary exacerbations.

Key Words: cystic fibrosis, hypertonic saline

Published Online, February 27, 2007. www.theannals.com, DOI 10.1345/aph.1H425

This article has been cited by other articles:

				D. K. Burchett, W. Darko, J. Zahra, J. Noviasky, L. Probst, and A. Smith Mixing and compatibility guide for commonly used aerosolized medications Am. J. Health Syst. Pharm., February 1, 2010; 67(3): 227 - 230. [Abstract] [Full Text] [PDF]